What are Ozempic and Rybelsus?
Ozempic and Rybelsus are both made by Novo Nordisk, and both contain semaglutide, a GLP-1 receptor agonist. The primary difference is how you take them.
Ozempic is a weekly injection using a pre-filled pen. It’s available at doses of 0.5 mg, 1 mg, and 2 mg (after an initial 0.25 mg titration phase).
Rybelsus is a daily oral tablet. It was originally available at doses of 3 mg, 7 mg, and 14 mg.
A new formulation with improved absorption was launched in the UK in late 2025, with doses of 1.5 mg, 4 mg, and 9 mg that provide equivalent clinical effects to the original doses.
Both are prescribed for type 2 diabetes when diet, exercise, and metformin alone aren’t providing sufficient blood sugar control. Neither is licensed for weight loss in the UK.
Same drug, different delivery
Because they contain the same molecule, both medications work in exactly the same way once in your bloodstream. Semaglutide mimics the GLP-1 hormone to:
- Slow food movement through your stomach, helping you feel fuller for longer
- Reduce hunger signals in your brain’s appetite centre
- Improve blood sugar control by enhancing insulin function
The critical difference is absorption. When injected, approximately 89% of semaglutide reaches your bloodstream. When taken orally, only about 1% is absorbed.3
This is why Rybelsus tablets contain much higher milligram amounts than Ozempic injections. The oral 14 mg tablet delivers roughly similar blood levels of semaglutide to the injectable 0.5-1 mg dose, because 99% of the oral dose isn’t absorbed.
Why is oral absorption so low?
Semaglutide is a peptide, a type of protein. Like most proteins, it would normally be destroyed by stomach acid and digestive enzymes before it could be absorbed.
Rybelsus tablets contain a special absorption enhancer called SNAC that temporarily protects semaglutide from stomach acid and helps it pass through the stomach lining.
Even with this technology, only about 1% makes it through, which is why the strict dosing requirements exist.3
Clinical evidence
No direct head-to-head trial
There’s no clinical trial that directly compared oral semaglutide (Rybelsus) to injectable semaglutide (Ozempic).
Instead, each was tested in its own trial programme: PIONEER for oral and SUSTAIN for injectable.
Indirect comparisons across these programmes and network meta-analyses suggest that injectable semaglutide produces approximately 1 kg more weight loss and a 0.2-0.3% greater reduction in HbA1c than oral semaglutide at their respective maximum doses.2
Oral semaglutide: the PIONEER programme
The PIONEER 1 trial tested oral semaglutide 14 mg in 703 people with type 2 diabetes over 26 weeks.1
Key results for oral semaglutide 14 mg:
- HbA1c reduction: -1.5% (vs -0.1% with placebo)
- 80% achieved HbA1c below 7.0% (vs 34% with placebo)
- Weight loss: 2.3-2.6 kg more than placebo
Injectable semaglutide: the SUSTAIN programme
Across the SUSTAIN trials in type 2 diabetes:
- Semaglutide 0.5 mg: HbA1c reduction of approximately -1.5%, weight loss of 3-5 kg
- Semaglutide 1 mg: HbA1c reduction of approximately -1.5% to -1.8%, weight loss of 4.5-6.5 kg
What explains the difference?
The slightly better results with injectable semaglutide likely reflect higher and more consistent drug levels in the blood.
Oral absorption varies depending on whether dosing instructions are followed perfectly, what you’ve eaten, and individual differences in stomach function. Injectable delivery bypasses these variables entirely.
Side effects and tolerability
Because both contain semaglutide, they share the same side effect profile.
The main difference is that Rybelsus tends to have slightly lower rates of gastrointestinal side effects, which may reflect the lower effective drug levels from oral absorption.
| Side effect |
Ozempic (injectable) |
Rybelsus (oral) |
| Nausea |
17-20%4 |
~15%5 |
| Diarrhoea |
12-13%4 |
~10%5 |
| Vomiting |
6-8%4 |
~7%5 |
| Constipation |
Common4 |
Common5 |
Most gastrointestinal side effects occur during dose escalation and reduce significantly over time with both formulations.
Discontinuation due to gastrointestinal side effects was approximately 4% with oral semaglutide in the PIONEER programme.1
Practical differences
Needles vs tablets
The most obvious difference. If you’re uncomfortable with injections, Rybelsus offers the same drug without needles. For many people, this is the deciding factor.
However, Rybelsus comes with strict dosing requirements that some people find inconvenient. Ozempic’s once-a-week injection is straightforward and can be taken at any time, with or without food.
Dosing requirements
Ozempic: Inject once a week on the same day each week. No food restrictions. Can be taken at any time of day.
Rybelsus: Take first thing in the morning on an empty stomach with a small sip of plain water only (no more than 120 ml). Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Do not crush, split, or chew the tablet.
These strict requirements exist because food, other liquids, and medications in the stomach significantly reduce semaglutide absorption from the tablet.3
Dosing frequency
Ozempic: 52 injections per year (once a week).
Rybelsus: 365 tablets per year (once a day). Missing a dose or not following the dosing instructions properly can reduce the medication’s effectiveness.
Storage
Ozempic: Refrigerate before first use. Once in use, store at room temperature (below 30°C) for up to 56 days.
Rybelsus: Store below 30°C. Protect from moisture by keeping it in the original blister until use. No refrigeration needed.
Cost and access in the UK
Both medications are available on the NHS for type 2 diabetes, subject to local prescribing guidelines. Rybelsus received NICE approval (NG28) for type 2 diabetes.6
On private prescription, typical monthly costs are:
- Ozempic: £150-250 per month, depending on dose and provider
- Rybelsus: £85-200 per month, depending on dose and provider
Neither medication is licensed for weight management. If weight loss is your primary goal, Mounjaro (tirzepatide) or Wegovy (semaglutide 2.4 mg) are the licensed options.
Who might prefer each option?
Ozempic might suit you if:
- You want the strongest effect from semaglutide – Injectable delivery provides higher, more consistent drug levels
- You prefer once-a-week dosing – One injection per week with no food restrictions
- You don’t mind injections – The pen is straightforward to use
- Your morning routine is unpredictable – No strict timing or fasting requirements
Rybelsus might suit you if:
- You want to avoid injections – The only oral GLP-1 medication available
- You have a consistent morning routine – Can reliably take it on an empty stomach and wait 30 minutes
- You’re starting GLP-1 treatment and prefer tablets – A good way to try semaglutide before considering injectables
- Cost is a factor – Generally less expensive on private prescription
Frequently asked questions
Is Ozempic more effective than Rybelsus?
Indirect comparisons suggest that injectable semaglutide (Ozempic) produces slightly greater weight loss and improvements in blood sugar than oral semaglutide (Rybelsus).2 This is primarily because injection delivers more consistent drug levels to your bloodstream than oral absorption, which is affected by food, stomach conditions, and individual variation.
Can I switch from Ozempic to Rybelsus?
Yes. Your prescriber can transition you between formulations. They’ll choose the appropriate Rybelsus dose based on your current Ozempic dose. Keep in mind that you may need to adjust to the strict morning dosing routine.
Can I take Ozempic and Rybelsus together?
No. Both contain semaglutide and should never be combined. Taking two forms of the same medication would effectively double your dose and significantly increase the risk of serious side effects.
Why does Rybelsus need to be taken on an empty stomach?
The absorption enhancer (SNAC) in Rybelsus tablets only works effectively on an empty stomach.
Food, other drinks, and medications interfere with the process, reducing how much semaglutide reaches your bloodstream. Even small deviations from the dosing instructions can significantly reduce the tablet’s effectiveness.3
Is Rybelsus a good alternative for people who hate needles?
Yes. Rybelsus is the only oral GLP-1 medication currently available. For people who are uncomfortable with injections, it provides access to semaglutide without needles. The trade-off is slightly lower effectiveness and strict daily dosing requirements.
Can I use Rybelsus for weight loss?
Rybelsus isn’t licensed for weight loss in the UK. It’s approved for type 2 diabetes only.
If you want semaglutide for weight management, Wegovy (injectable semaglutide 7.4 mg) is the licensed option and provides significantly greater weight loss than either Rybelsus or Ozempic.
What happens if I eat before the 30-minute wait with Rybelsus?
Eating before 30 minutes reduces absorption of semaglutide, meaning less medication reaches your bloodstream. This can make the tablet less effective for blood sugar control. If this happens occasionally, it’s not dangerous, but consistently failing to follow the instructions will reduce the medication’s benefits.
Has Rybelsus changed its doses?
Yes. In late 2025, Novo Nordisk launched a new formulation of Rybelsus in the UK with improved absorption.
The new doses (1.5 mg, 4 mg, 9 mg) replace the original doses (3 mg, 7 mg, 14 mg) and provide equivalent clinical effects. The dosing instructions remain the same.
Which is better for long-term use?
Both are designed for long-term use in type 2 diabetes. Injectable semaglutide may have a practical advantage because once-a-week dosing is easier to maintain consistently than daily tablets, which require strict adherence. Adherence to medication regimens tends to be better with less frequent dosing.
Does Rybelsus cause fewer side effects than Ozempic?
Rybelsus tends to have slightly lower rates of gastrointestinal side effects, likely because less semaglutide reaches the bloodstream compared with injection.
However, both medications cause similar types of side effects, primarily nausea, diarrhoea, and vomiting during dose escalation.4,5
Take home message
Ozempic and Rybelsus contain the same drug but offer different ways of taking it.
Injectable semaglutide (Ozempic) delivers slightly better blood sugar control and weight loss due to more efficient drug absorption, while oral semaglutide (Rybelsus) avoids injections entirely.
The choice often comes down to personal preference. If you’re comfortable with a weekly injection and want the strongest effect, Ozempic is likely the better option.
If you want to avoid injections and you can commit to the strict morning dosing routine, Rybelsus provides the same medication without injections.
Both are effective treatments for type 2 diabetes. Neither is licensed for weight loss. If weight management is your primary goal, Mounjaro (tirzepatide) or Wegovy (semaglutide 7.4 mg) are the appropriate options.
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
References
- Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-1732. https://diabetesjournals.org/care/article/42/9/1724/36289/PIONEER-1-Randomized-Clinical-Trial-of-the
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. https://www.nejm.org/doi/full/10.1056/NEJMoa1901118
- Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. https://www.science.org/doi/10.1126/scitranslmed.aar7047
- Electronic Medicines Compendium. Ozempic 0.25 mg, 0.5 mg, 1 mg solution for injection in pre-filled pen – Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/9748/smpc
- Electronic Medicines Compendium. Rybelsus 14 mg tablets – Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14389/smpc
- National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (NG28). https://www.nice.org.uk/guidance/ng28
